List of Lymphoseek Kit drug patents

Lymphoseek Kit is owned by Cardinal Health 414.

Lymphoseek Kit contains Technetium Tc-99M Tilmanocept.

Lymphoseek Kit has a total of 2 drug patents out of which 0 drug patents have expired.

Lymphoseek Kit was authorised for market use on 13 March, 2013.

Lymphoseek Kit is available in injectable;injection dosage forms.

The generics of Lymphoseek Kit are possible to be released after 30 January, 2029.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6409990 CARDINAL HEALTH 414 Macromolecular carrier for drug and diagnostic agent delivery
May, 2025

(2 years from now)

US9439985 CARDINAL HEALTH 414 Compositions for radiolabeling diethylenetriaminepentaacetic acid (DTPA)-dextran
Jan, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) May 19, 2024

Drugs and Companies using TECHNETIUM TC-99M TILMANOCEPT ingredient

Market Authorisation Date: 13 March, 2013

Treatment: NA

Dosage: INJECTABLE;INJECTION

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic